# US 2026/0152636 A1 · Gelling solutions for administration of compounds to the inner ear

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0152636 A1
- Document ID: US20260152636A1
- Status: Published application
- Kind: A1
- Application number: 19/463,990
- Filed: 2026-01-29
- Published: 2026-06-04
- Earliest claimed: 2020-05-13
- Assignees: Spiral Therapeutics Inc.
- Applicants: Spiral Therapeutics, Inc.
- Inventors: Eugene de Juan, SR.; Signe Erickson; Andrew Ayoob; Kathleen Cogan Farinas
- Web page: https://patentgrep.com/patent/US20260152636A1

## CPC

- C08L 71/00: Compositions of polyethers obtained by reactions forming an ether link in the main chain (of polyacetals C08L59/00; of epoxy resins C08L63/00; of polythioether-ethers C08L81/02; of polyether-sulfones C08L81/06); Compositions of derivatives of such polymers
- A61K 9/0046: {Ear}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 27/16: Otologicals
- C08L 77/04: Polyamides derived from alpha-amino carboxylic acids (C08L77/10 takes precedence)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are polymer compositions and extended release otic agents. In one aspect, provided herein is a polymer composition including about 5% to about 15% by weight of the polymer composition of a functional polymer, wherein the functional polymer includes a first functional group, about 0.05% to about 0.6% by weight of the polymer composition of a crosslinker, wherein the crosslinker includes a second functional group, and water, wherein a crosslinking reaction can occur between the first functional group and the second functional group to form a gel, and wherein the polymer composition has a gelation time of about 45 seconds to about 60 minutes at a temperature of about 20° C.

## Claims

### Claim 1

A method of positioning a treatment gel into contact with a round window membrane of a cochlea of the subject while under visualization, the method comprising:
administering through an otic delivery cannula about 40 μL to about 60 μL of a treatment gel into contact with the round window membrane of the cochlea of the subject such that the treatment gel remains at the round window membrane of the cochlea for a residence time of at least 5 days, wherein said treatment gel comprises a cross-linking polymer composition having a pH of about 5.5 to about 6.0 and a gelation time of about 2 minutes to about 8 minutes at a temperature of about 37° C., said cross-linking polymer composition consisting of: (i) a first functional polymer in an amount of about 5% to about 15% by weight of the polymer composition, (ii) a crosslinker in an amount of about 0.05% to about 0.6% by weight of the polymer composition so as to provide a gel formation reaction with said first functional polymer, (iii) sodium phosphate in an amount of about 0.01% to about 3.0% of the polymer composition, (iv) water, and (v) a dye; and
during said administering through the otic delivery cannula, providing direct visualization of the treatment gel being deposited into contact with the round window membrane of the cochlea of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein said administering comprises urging the treatment gel from a syringe and through the otic delivery cannula having a diameter of 23G or smaller before said treatment gel transitions within the said gelation time from a flowable liquid to a gel substance.

### Claim 3 (depends on 2)

The method of claim 2, further comprising, prior to said administering, inserting the otic delivery cannula having the diameter of 23G or smaller through a tympanic membrane and toward the round window membrane of the cochlea of the subject.

### Claim 4 (depends on 2)

The method of claim 2, wherein said administering comprises inserting the otic delivery cannula toward the round window membrane of the cochlea of the subject through a mastoidectomy approach.

### Claim 5 (depends on 1)

The method of claim 1, wherein said administering comprises depositing about 40 μL to about 60 μL of the treatment gel into contact with the round window membrane of the cochlea of the subject while the treatment gel does not contact any of ossicles of the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein said providing direct visualization of the treatment gel being deposited into contact with the round window membrane comprises using an endoscope instrument.

### Claim 7 (depends on 1)

The method of claim 1, wherein said treatment gel comprises said cross-linking polymer composition and an anti-inflammatory active agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein said treatment gel remains at the round window membrane of the cochlea for said residence time and delivers a sustained release of said anti-inflammatory active agent into the cochlea of the subject for a period of about 5 days to about 2 months.

### Claim 9 (depends on 8)

The method of claim 8, wherein the active agent comprises dexamethasone present in an amount of about 1% to about 10% by weight of said treatment gel.

### Claim 10 (depends on 1)

The method of claim 1, further comprising, prior to said administering the treatment gel into contact with the round window membrane of the cochlea, using delayed intravenous gadolinium contrast enhanced 3T MRI to evaluate the subject for a first level of endolymphatic hydrops, perilymphatic enhancement, or both.

### Claim 11 (depends on 10)

The method of claim 10, further comprising, after said administering the treatment gel into contact with the round window membrane of the cochlea, using a second instance of delayed intravenous gadolinium contrast enhanced 3T MRI to evaluate the subject for a subsequent level of endolymphatic hydrops, perilymphatic enhancement, or both.

### Claim 12 (depends on 11)

The method of claim 11, wherein said second instance of delayed intravenous gadolinium contrast enhanced 3T MRI provides an evaluation of the subject for the subsequent level about fifteen days after said administering the treatment gel into contact with the round window membrane of the cochlea.

### Claim 13 (depends on 1)

The method of claim 1, wherein said first functional polymer comprises pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate in an amount of about 5% to about 15% by weight of the polymer composition.

### Claim 14 (depends on 13)

The method of claim 13, wherein said crosslinker comprises trilysine, or a salt thereof, in an amount of about 0.1% to about 0.3% by weight of the polymer composition so as to provide the gel formation reaction with said pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate.

### Claim 15 (depends on 1)

The method of claim 1, wherein the treatment gel transitions within the said gelation time from a flowable liquid to a gel substance that is elastic or mucoadhesive.

### Claim 16 (depends on 1)

The method of claim 1, wherein the treatment gel transitions within the said gelation time from a flowable liquid to a gel substance that has an osmolality of about 300 mOsmol/kg to about 600 mOsmol/kg.

### Claim 17 (depends on 1)

The method of claim 1, wherein the treatment gel is configured to swell less than 100% following equilibration in phosphate-buffered saline (PBS) for 1 day.

### Claim 18 (depends on 1)

The method of claim 1, wherein the treatment gel remains at the round window membrane of the cochlea for the residence time of at least 14 days.
